Good news for parents: There are now more once-daily treatment options for the tiniest members of the HIV community.
In the updated Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, the Department of Health and Human Services says that Tivicay PD (dolutegravir) and Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) are the preferred medications for children living with HIV. Both require just once-daily dosing. Twice-daily dosing is part of why Isentress (raltegravir) and Selzentry (maraviroc) were downgraded to alternatives this year.
Specifically, the guidelines recommend water-dispersible Tivicay PD for treatment-experienced infants as young as 4 weeks old and Biktarvy for children at least 6 years old. Tivicay PD should be taken with two nucleoside reverse transcriptase inhibitors.